136 related articles for article (PubMed ID: 35239111)
1. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
de Marcellus C; Tauziède-Espariat A; Cuinet A; Pasqualini C; Robert MP; Beccaria K; Puget S; Boddaert N; Figarella-Branger D; De Carli E; Bourdeaut F; Leblond P; Fouyssac F; Andre N; Bertozzi AI; Butel T; Dufour C; Valteau-Couanet D; Varlet P; Grill J
J Neurooncol; 2022 Apr; 157(2):355-364. PubMed ID: 35239111
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Kalra M; Heath JA; Kellie SJ; Dalla Pozza L; Stevens MM; Swamy S; McCowage GB
J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
[TBL] [Abstract][Full Text] [Related]
4. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
[TBL] [Abstract][Full Text] [Related]
6. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Demirci U; Tufan G; Aktas B; Balakan O; Alacacioglu A; Dane F; Engin H; Kaplan MA; Gunaydin Y; Ozdemir NY; Tugba Unek I; Karaca H; Akman T; Sonmez OU; Coskun U; Harputluoglu H; Sevinc A; Tonyali O; Buyukberber S; Benekli M
J Cancer Res Clin Oncol; 2013 May; 139(5):829-35. PubMed ID: 23400732
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Kang TY; Jin T; Elinzano H; Peereboom D
J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
11. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
[TBL] [Abstract][Full Text] [Related]
12. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Bokstein F; Shpigel S; Blumenthal DT
Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
[TBL] [Abstract][Full Text] [Related]
13. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
Roux C; Revon-Rivière G; Gentet JC; Verschuur A; Scavarda D; Saultier P; Appay R; Padovani L; André N
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e630-e634. PubMed ID: 33235152
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.
Couec ML; André N; Thebaud E; Minckes O; Rialland X; Corradini N; Aerts I; Marec Bérard P; Bourdeaut F; Leblond P;
Pediatr Blood Cancer; 2012 Jul; 59(1):34-8. PubMed ID: 22287258
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
[TBL] [Abstract][Full Text] [Related]
18. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Gajjar A; Goldman S; Friedman HS; Packer RJ; Boyett JM; Kun LE; McLendon R
Neuro Oncol; 2012 Nov; 14(11):1404-12. PubMed ID: 23019233
[TBL] [Abstract][Full Text] [Related]
19. Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
Heng MA; Padovani L; Dory-Lautrec P; Gentet JC; Verschuur A; Pasquier E; Figarella-Branger D; Scavarda D; André N
Cancer Med; 2016 Jul; 5(7):1542-5. PubMed ID: 27037940
[TBL] [Abstract][Full Text] [Related]
20. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
